Acute myocardial infarction and acute kidney injury are life-threatening conditions caused by ischemia, resulting from reduced or blocked blood flow to organs. Although early restoration of blood flow ...

Please provide your email address to receive an email when new articles are posted on . Patients with a history of myocardial infarction are unlikely to receive prescriptions for ...

Researchers from the Cardiac Regeneration and Heart Failure Research Group (ICREC) at the Germans Trias i Pujol Research Institute (IGTP) and the Heart Institute of the Germans Trias Hospital(iCor) ...

The German Institute for Quality and Efficiency in Health Care (IQWiG) assessed the added benefit of ticagrelor for patients with acute coronary syndrome already in 2011 in its very first dossier ...

The proof of efficacy of thrombolysis for acute myocardial infarction (AMI) depends on 9 randomized placebo-controlled trials totaling 58,511 patients. The meta-analysis of these trials showed an ...

Brexogen has initiated clinical trials for its myocardial infarction treatment developed using its proprietary platform technology. On May 13, Brexog ...

Researchers from the Germans Trias i Pujol research institute (IGTP) have conducted a preclinical study on the effects of the drug empagliflozin, alone or in combination with sacubitril/valsartan, in ...

A massive international study could upend 40 years of heart attack treatment. Researchers found that beta blockers—routinely prescribed after uncomplicated heart attacks—offered no real benefit for ...

These words uttered in 1901 relate directly to studies of thrombolytics for AMI. In GISSI-1 and 2 other major thrombolysis trials, the investigators did not require an informed consent of the patients ...